Blood Substitutes

Phase III PolyHeme Trials Cleared by FDA

Published in AIDS Weekly, April 21st, 1997

Northfield Laboratories, Inc., Evanston, Illinois, has received clearance from the U.S. Food and Drug Administration (FDA) to begin Phase III trials of PolyHeme.

PolyHeme is a blood substitute. The pivotal trials, the first Phase III studies to include direct replacement of blood in large volumes, mark a milestone in medicine's search for an oxygen-carrying blood substitute, the company said.

Under the Phase III protocol cleared by the FDA, surgical patients are infused with six units of PolyHeme, Northfield's proprietary blood substitute. The six-unit level (3 liters containing 300 grams of hemoglobin) represents approximately 60 percent of an...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry